Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creatine Augmentation for ECT in MDD
NCT04504253Phase 3Completed
- Sponsor
- University of Utah
- Start
- Aug 2020
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (2 arms), sponsored by University of Utah. Primary endpoint: 17-item Hamilton Depression Rating Scale at 6 weeks. Started Aug 2020; status: completed.
Beyond the preview
Go deeper on NCT04504253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504253.